SynthesisThe Cochrane database of systematic reviews2000
Interventions for treating schistosomiasis haematobium.
Synthesis in The Cochrane database of systematic reviews, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Drugs for treating urinary schistosomiasis.The Cochrane database of systematic reviews · 2014Pooled it
- [Therapy of tropical diseases after returning from travel].Der Internist · 2003Review
Corrections and comments
- Updated by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchistosomiasis is a parasite that is carried by freshwater snails. There are two common forms, urinary schistosomiasis (which is considered in this review) and intestinal schistosomiasis.
objectivesThe objective of this review was to assess the effects of drugs for treatment of Schistosomiasis haematobium. SEARCH STRATEGY: The Cochrane Infectious Diseases Group trials register, Medline and reference lists of articles were searched. The WHO Division of Control of Tropical Diseases was contacted. SELECTION CRITERIA: Randomised trials of metrifonate or praziquantel or other drugs for treating Schistosomiasis haematobium. DATA COLLECTION AND ANALYSIS: One reviewer assessed trial quality and extracted data, and this was checked by a review editor. MAIN
resultsFive trials, all from Africa, were included. The quality of the trials was variable. There were no good randomised controlled trials of praziquantel single dose treatment versus current standard treatment with metrifonate of three doses of 10 milligrams per kilogram at two weekly intervals. Praziquantel at doses of 40 milligram per kilogram was more effective than single dose metrifonate 10 milligrams per kilogram (odds ratio 6.94, 95% confidence interval 4.85 to 9.92). In one trial of metrifonate compared with praziquantel, there was no difference demonstrated in a range of clinical outcomes including cessation of haematuria and proteinuria. Both drugs improved nutritional status and physical fitness. REVIEWER'S
conclusionsPraziquantel (single dose) appears to be more effective than metrifonate (split dose) in terms of parasitological cure of Schistosomiasis haematobium, but the reinfection rate is high with both drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.